
|Videos|December 13, 2021
Expert: Chronic Lymphocytic Leukemia Can Effect Younger Individuals
Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how common chronic lymphocytic leukemia is for younger individuals
Advertisement
In a Pharmacy Times® Interview, Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses his oral presentation at ASH 2021 of the Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia (CLL).
He discussed how common CLL is for younger individuals.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Obinutuzumab-Bendamustine Produces High Response Rates in Chinese Patients With Indolent B-Cell Lymphomas
2
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
3
Dosing, Monitoring, and Counseling: The Pharmacist's Role in TKI Therapy for Systemic Mastocytosis
4
What Pharmacists Should Know About the Ifosfamide Shortage
5





































































































